1.810CADMkt Cap: 208.64M CADP/E: —Last update: 2026-05-21
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx,…
Industry Peers
Drug Manufacturers - Specialty & Generic153.14BSEKP/E 168.3
54.96BEURP/E 21.7
52.53BTRYP/E 27.3
33.63BPLNP/E 21.9
13.36BSEKP/E 40.3
13.24BEURP/E 30.2
12.58BTRY—
3.96BUSDP/E 33.6
loading…
Indicators:|
Key Statistics
Company
Market Cap208.64M CAD
Enterprise Value169.71M CAD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-33.82M CAD
Revenue/Share—
Last Price1.810 CAD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees18
CountryCA
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.46
PEG—
EV/EBITDA-4.77
EV/Revenue—
P/S—
P/B10.17
EPS (TTM)-0.39
EPS (Forward)-0.28
52W Range
1.77067% of range1.830
52W High1.830 CAD
52W Low1.770 CAD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-189.17%
ROA-143.18%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-23.85M CAD
CapEx (TTM)24.48K CAD
FCF Margin—
FCF Yield-6.59%
Net Debt-27.56M CAD
Net Debt/EBITDA0.78
Balance Sheet
Debt/Equity0.01
Current Ratio4.39
Quick Ratio3.93
Book Value/Sh0.1780 CAD
Cash/Share0.2540 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CAD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)6.000 CAD
Target Range5.000 CAD – 7.000 CAD
# Analysts2
Ownership
Shares Out.115.27M
Float94.00M
Insiders2.43%
Institutions25.68%
Short Interest
Short Ratio1.0d
Short % Float0.17%
Short % Out.0.16%
Shares Short180.04K
Short (prev mo.)159.18K
Technical
SMA 501.768 (+2.4%)
SMA 2001.538 (+17.7%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)32.87K
Avg Vol (10d)66.36K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—